Is ARTELO BIOSCIENCES, INC. (ARTL) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 28.0% / 30% | 24.8% / 30% | 0.0% / 30% | N/A | ✓ HALAL |
| DJIM | 28.0% / 33% | 24.8% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| MSCI | 24.2% / 33% | 21.4% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| S&P | 28.0% / 33% | 24.8% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| FTSE | 24.2% / 33% | 21.4% / 33% | 0.0% / 50% | N/A | ✓ HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -1625.1% | |
| Return on Assets (ROA) | -190.1% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$9M |
| Free Cash Flow | -$9M |
| Total Debt | $678,000 |
| Current Ratio | 0.2 |
| Total Assets | $3M |
Price & Trading
| Last Close | $3.19 |
| 50-Day MA | $4.67 |
| 200-Day MA | $15.00 |
| Avg Volume | 1.2M |
| Beta | 1.1 |
|
52-Week Range
$2.96
| |
About ARTELO BIOSCIENCES, INC. (ARTL)
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; and ART12.11, a cocrystal composition of cannabidiol and tetramethylpyrazine for the treatment anxiety, depression, post-traumatic stress disorder PTSD, epilepsy and insomnia, and other potential indications. It also offers ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is ARTELO BIOSCIENCES, INC. (ARTL) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), ARTELO BIOSCIENCES, INC. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is ARTELO BIOSCIENCES, INC.'s debt ratio?
ARTELO BIOSCIENCES, INC.'s debt ratio is 28.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 24.2%.
What are ARTELO BIOSCIENCES, INC.'s key financial metrics?
ARTELO BIOSCIENCES, INC. has a market capitalization of $8M. Return on equity stands at -1625.1%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.